Results 41 to 50 of about 51,662 (290)

Cold atmospheric plasma‐mediated tumor microenvironment remodeling for cancer treatment

open access: yesBMEMat, EarlyView.
Schematic presentation of CAP‐mediated TME remodeling. This review summarizes recent efforts in cold atmospheric plasma (CAP) application in cancer treatment, highlighting the anticancer potential of CAP, molecular mechanisms, and future perspectives for further improvement and clinical translation.
Israr Khan   +8 more
wiley   +1 more source

Lack of PRAME Expression in Cutaneous T-Cell Lymphomas

open access: yesDermatopathology, 2021
Cutaneous T-cell lymphomas (CTCLs) are rare tumors with no established markers that can reliably distinguish between benign and malignant lesions. Preferentially Expressed Antigen in Melanoma (PRAME) is a cancer/testis antigen that is found in many solid
Chau M. Bui   +4 more
doaj   +1 more source

Neoadjuvant Immunotherapy for Periauricular Cutaneous Squamous Cell Carcinoma

open access: yesHead &Neck, EarlyView.
ABSTRACT Background The standard‐of‐care for advanced periauricular cutaneous squamous cell carcinoma (pCSCC) is surgery and adjuvant radiation therapy. Neoadjuvant immunotherapy recently demonstrated high pathologic response rates in patients with resectable pCSCC.
David Z. Allen   +6 more
wiley   +1 more source

Clinical characteristics, treatment response, and survival outcomes in melanoma patients with cavity carcinomatosis: A retrospective analysis

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Cavity carcinomatosis, a late manifestation of cancer, fuels tumor formation throughout a large area, most commonly the peritoneal and pleural cavities. The condition also can lead to resistance to otherwise effective treatment strategies.
Zhongqiao Lin   +6 more
wiley   +1 more source

Characteristics and overall survival in patients with T1 melanoma: A nationwide matched cohort study

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Thin cutaneous malignant melanoma has an excellent ten‐year melanoma‐specific survival of 93%–97%. Moreover, the incidence of melanoma is higher among individuals with high socioeconomic status, which may protect them from other diseases. This nationwide matched cohort study found that patients with thin cutaneous malignant melanoma have a ...
Ylva Naeser   +4 more
wiley   +1 more source

Silent T-cell receptor cutaneous T-cell lymphoma associated to a clonal plasma cell proliferation

open access: yesHematology Reports, 2019
Within T-cell lymphomas (TCL) there are 2 entities expressing gamma-delta TCR: hepatosplenic gamma-delta T-cell lymphoma (HSGDTL) and the primary cutaneous gamma-delta T-cell lymphoma (PCGDTL).
Ana Caballero   +6 more
doaj   +1 more source

Extracellular vesicle‐based vaccines and immunotherapeutics for treatment of cancer

open access: yesInterdisciplinary Medicine, EarlyView.
This review highlights the innovative value of extracellular vesicles (EVs) as cancer vaccines and immunotherapy carriers. EVs have natural advantages such as low immunogenicity, high biocompatibility, stability, and precise targeting, enabling efficient delivery of tumor antigens (e.g., HER2, AFP) and immune stimulants (e.g., TLR ligands, cytokines ...
Lejia Tan   +4 more
wiley   +1 more source

Breast implant-associated anaplastic large cell lymphoma: A review and assessment of cutaneous manifestations

open access: yesInternational Journal of Women's Dermatology, 2017
One newly recognized form of T-cell lymphoma is breast implant-associated anaplastic large cell lymphoma (biALCL), which appears in close proximity to breast implants. The number of reported cases of biALCL is increasing and warrants careful attention by
N. Shahriari, MD   +2 more
doaj   +1 more source

Dupilumab and Systemic Hematologic Malignancies: Case Series and Literature Review

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting 15%–20% of children and 3%–10% of adults. An increased risk of systemic lymphomas – but not leukemias – has been reported in patients with AD. Dupilumab, a monoclonal IgG4 antibody targeting IL‐4 and IL‐13 signaling, is approved for moderate‐to‐severe AD and is ...
Nello Tommasino   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy